Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11362161 | 0.82 | TDP1 (0.52) | ACHEMAOBBCHE | |
| SCHEMBL11370553 | 0.81 | TDP1 (0.55) | ACHEMAOBBCHE | |
| SCHEMBL11371968 | 0.79 | ACHE (0.60) | ACHEBCHE | |
| SCHEMBL10743632 | 0.79 | ALDH1A1 (0.55) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL11364469 | 0.79 | ALDH1A1 (0.55) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL11367172 | 0.78 | ACHE (0.44) | ACHEMAOBSMN1; SMN2BCHE | |
| SCHEMBL11013833 | 0.77 | ACHE (0.62) | ACHEBCHE | |
| SCHEMBL11372202 | 0.77 | ACHE (0.66) | ACHEBCHE | |
| SCHEMBL6701969 | 0.75 | ALDH1A1 (0.48) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL19695649 | 0.75 | ALDH1A1 (0.48) | ALDH1A1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354092-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2468734-A1 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | Siemens Medical Solutions USA, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2008124703-A2 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | ALDH1A1 387/4885POLB 4826/4885ACHE 1869/4885 |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | CA9, CA4, CA13 | ALDH1A1 387/4885POLB 4826/4885ACHE 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.